Tvardi Therapeutics, Inc. TVRD
1.10 USD -0.08 (-6.78%)
Regular-session close
1.06 -0.04 -3.64%
After hours · Nov 16, 7:18 PM ET
1.06 Day range 1.17
0.793 52-week range 5.00
- YTD
- -74.42%
- 1 year
- -72.70%
News
benzinga.com Tvardi Therapeutics Q3 EPS $(0.48) Beats $(0.53) Estimate Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 18.64 percent increase over losses of…
globenewswire.com Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral,…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…benzinga.com Chardan Capital Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $8 Chardan Capital analyst Gautam Chukka initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $8.
